Heidelberg Pharma AG (HPHA) | Finanzwire

Basculer en Français

8301	Companies
115073	Keywords
55422	Articles
62513	Press releases

Home
Companies
Heidelberg Pharma AG

BRIEF

published on 03/18/2024 at 07:30, 8 months 3 days ago

Heidelberg Pharma Advances to Cohort 6 in Multiple Myeloma Study with HDP-101

Heidelberg Pharma HDP-101 Multiple Myeloma Phase I/IIa Study Cohort 6
PRESS RELEASE

published on 03/18/2024 at 07:25, 8 months 3 days ago

Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study
Heidelberg Pharma progresses into Cohort 6 with ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study, showing first objective responses and partial remissions. Amended protocol includes optimized dosing regimens

Heidelberg Pharma Multiple Myeloma Phase I/IIa Study ATAC Candidate Protocol Amendment
BRIEF

published on 03/06/2024 at 07:51, 8 months 15 days ago

Heidelberg Pharma to Showcase HDP-101 Efficacy and ADC Technology at AACR 2024

Cancer Research Heidelberg Pharma HDP-101 ADC Technology AACR Meeting 2024
PRESS RELEASE

published on 03/06/2024 at 07:46, 8 months 15 days ago

Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024
Heidelberg Pharma to present first efficacy data on HDP-101 and data from proprietary ADC technology platform at AACR Meeting 2024. Details of ATAC and ADC-based cancer therapies

Clinical Trials Heidelberg Pharma ADC Technology AACR Meeting 2024 ATAC Therapies
BRIEF

published on 03/04/2024 at 11:24, 8 months 17 days ago

Heidelberg Pharma Secures Up to $115 Million in Royalty Financing from HealthCare Royalty

Biopharmaceuticals Heidelberg Pharma HealthCare Royalty Royalty Financing ZircaixTM
PRESS RELEASE

published on 03/04/2024 at 11:19, 8 months 17 days ago

Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
Heidelberg Pharma announces royalty financing agreement with HealthCare Royalty for up to USD 115 million. Agreement to purchase royalties from Telix Pharmaceuticals for Zircaix(TM)

Biotech Heidelberg Pharma HealthCare Royalty Royalty Financing Zircaix
BRIEF

published on 03/04/2024 at 11:07, 8 months 17 days ago

Heidelberg Pharma Secures Royalty Financing Deal Worth Up to $115 Million with HealthCare Royalty

Oncology Heidelberg Pharma HealthCare Royalty Royalty Financing Zircaix
PRESS RELEASE

published on 03/04/2024 at 11:02, 8 months 17 days ago

EQS-Adhoc: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
Heidelberg Pharma announces royalty financing agreement with HealthCare Royalty for up to USD 115 million. Agreement involves royalties from worldwide sales of Telix Pharmaceuticals' ZircaixTM

Heidelberg Pharma HealthCare Royalty Royalty Financing Telix Pharmaceuticals ZircaixTM
PRESS RELEASE

published on 11/02/2023 at 16:34, 1 year ago

Heidelberg Pharma Presents New Clinical Data from its Lead Candidate HDP-101 at the ASH Annual Meeting 2023
PRESS RELEASE

published on 10/12/2023 at 07:09, 1 year 1 month ago

Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2023

Accesswire

Published on 11/21/2024 at 17:35, 1 hour 28 minutes ago

1upHealth Ranked Number 43 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500(TM)
Published on 11/21/2024 at 17:30, 1 hour 33 minutes ago

SimpliGov and Proof Partner to Offer Online Notarization
Published on 11/21/2024 at 16:30, 2 hours 33 minutes ago

The Rise of DINKs: Dual-Income Couples Without Kids Redefine Financial Priorities in America
Published on 11/21/2024 at 16:01, 3 hours 2 minutes ago

Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 3 hours 3 minutes ago

Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 18:36, 26 minutes ago

Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 1 hour 4 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 1 hour 11 minutes ago

LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 1 hour 11 minutes ago

2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.
Published on 11/21/2024 at 16:00, 3 hours 3 minutes ago

Director/PDMR Shareholding

Les Echos

Published on 11/21/2024 at 06:58, 12 hours 5 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 23 hours 43 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 1 hour ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 1 hour ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 11 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE